IM-01 PI3K GAMMA INHIBITOR FOR OVERCOMING TREATMENT RESISTANCE IN COMBINATION THERAPY OF TEMOZOLOMIDE AND ANTI-PDL1 ANTIBODY FOR GLIOBLASTOMA PATIENTS

PURPOSE: Multidisciplinary therapies including immunotherapy in glioblastoma (GBM) patients often cause long survivor, while early relapse of GBM still remains. We should find factors associated with the immunotherapy-resistance for overcoming it. We previously reported that the infiltration of PD-1...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurooncol Adv
Main Authors: Ishikawa, Eiichi, Miyazaki, Tsubasa, Matsuda, Masahide, Takano, Shingo, Matsumura, Akira
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213340/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.051
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki